- Home
- FEMY vs NRXS Comparison
FEMY vs NRXS Comparison
Compare FEMY & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- NRXS
- Stock Information
- Founded
- FEMY 2004
- NRXS 2011
- Country
- FEMY United States
- NRXS United States
- Employees
- FEMY 34
- NRXS N/A
- Industry
- FEMY Medical/Dental Instruments
- NRXS
- Sector
- FEMY Health Care
- NRXS
- Exchange
- FEMY Nasdaq
- NRXS Nasdaq
- Market Cap
- FEMY 22.4M
- NRXS 20.3M
- IPO Year
- FEMY 2021
- NRXS 2023
- Fundamental
- Price
- FEMY $0.97
- NRXS $3.15
- Analyst Decision
- FEMY Strong Buy
- NRXS
- Analyst Count
- FEMY 3
- NRXS 0
- Target Price
- FEMY $10.00
- NRXS N/A
- AVG Volume (30 Days)
- FEMY 263.1K
- NRXS 24.7K
- Earning Date
- FEMY 11-12-2024
- NRXS 11-12-2024
- Dividend Yield
- FEMY N/A
- NRXS N/A
- EPS Growth
- FEMY N/A
- NRXS N/A
- EPS
- FEMY N/A
- NRXS N/A
- Revenue
- FEMY $1,260,643.00
- NRXS $2,456,219.00
- Revenue This Year
- FEMY $135.27
- NRXS $383.16
- Revenue Next Year
- FEMY $310.75
- NRXS N/A
- P/E Ratio
- FEMY N/A
- NRXS N/A
- Revenue Growth
- FEMY 15.33
- NRXS N/A
- 52 Week Low
- FEMY $0.73
- NRXS $2.00
- 52 Week High
- FEMY $2.40
- NRXS $3.89
- Technical
- Relative Strength Index (RSI)
- FEMY 37.55
- NRXS 57.49
- Support Level
- FEMY $0.86
- NRXS $3.03
- Resistance Level
- FEMY $1.18
- NRXS $3.31
- Average True Range (ATR)
- FEMY 0.08
- NRXS 0.39
- MACD
- FEMY -0.02
- NRXS 0.06
- Stochastic Oscillator
- FEMY 24.39
- NRXS 61.59
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).